EGFR (Epidermal Growth Factor Receptor), also known as HER1 or ErbB1, is a 170 kDa transmembrane receptor tyrosine kinase that plays critical roles in cell proliferation, survival, differentiation, and migration. While extensively studied in cancer biology, EGFR has emerged as an important player in neuroscience and neurodegenerative diseases, including Alzheimer's Disease, Parkinson's Disease, and various neurological disorders.
| Epidermal Growth Factor Receptor |
|---|
| Gene Symbol | EGFR |
| Full Name | Epidermal Growth Factor Receptor |
| Chromosome | 7p11.2 |
| NCBI Gene ID | [1956](https://www.ncbi.nlm.nih.gov/gene/1956) |
| OMIM | 131550 |
| Ensembl ID | ENSG00000146648 |
| UniProt ID | [P00533](https://www.uniprot.org/uniprot/P00533) |
| Protein Length | 1210 amino acids |
| Protein Class | Receptor tyrosine kinase (RTK) |
| Attribute |
Value |
| Gene Symbol |
EGFR (HER1, ErbB1) |
| Full Name |
Epidermal Growth Factor Receptor |
| Chromosomal Location |
7p11.2 |
| NCBI Gene ID |
1956 |
| OMIM |
131550 |
| Ensembl ID |
ENSG00000146648 |
| UniProt ID |
P00533 |
| Protein Length |
1210 amino acids |
| Molecular Weight |
~170 kDa |
| Expression |
Ubiquitous, highest in epithelial cells, neurons, astrocytes |
¶ Discovery and Nomenclature
EGFR was discovered in the 1970s as the cellular homolog of the viral oncogene v-erbB, making it one of the first characterized receptor tyrosine kinases. The name reflects its original identification as the receptor for epidermal growth factor (EGF), though subsequent research revealed multiple ligands and functions.
¶ Domain Architecture
EGFR is a type I transmembrane receptor consisting of[@kumar2020]:
-
Extracellular domain (residues 1-621)
- Ligand-binding region
- Four subdomains (I-IV)
- Contains cysteine-rich motifs
-
Transmembrane domain (residues 622-644)
- Single alpha-helix
- Anchors receptor in plasma membrane
-
Intracellular domain (residues 645-1210)
- Tyrosine kinase domain (645-974)
- C-terminal regulatory tail with tyrosine residues
- Multiple phosphorylation sites
EGFR activation involves:
- Ligand binding: EGF, TGF-α, amphiregulin, HB-EGF
- Dimerization: Formation of homodimers or heterodimers with other ErbB family members
- Autophosphorylation: Activation of kinase domain and phosphorylation of tyrosine residues
- Signal transduction: Recruitment of downstream adaptor proteins
EGFR is one of four members of the ErbB receptor family[@yarden2001]:
| Receptor |
Other Names |
Ligands |
| EGFR |
HER1, ErbB1 |
EGF, TGF-α, amphiregulin |
| HER2/neu |
ErbB2 |
None (ligandless) |
| HER3 |
ErbB3 |
Neuregulins |
| HER4 |
ErbB4 |
Neuregulins, NRG-4 |
The family functions as a coordinated network, with heterodimerization expanding signaling diversity.
EGFR activates multiple downstream signaling cascades:
-
RAS/RAF/MEK/ERK pathway (MAPK)
- Cell proliferation and differentiation
- Gene expression changes
-
PI3K/AKT/mTOR pathway
- Cell survival and metabolism
- Protein synthesis
- Anti-apoptotic signaling
-
JAK/STAT pathway
- Gene transcription
- Cell growth and differentiation
-
PLC-γ pathway
- Calcium signaling
- PKC activation
- Proliferation: Stimulates cell cycle progression (G1 to S phase)
- Survival: Anti-apoptotic signaling via AKT
- Differentiation: Role in development and tissue maintenance
- Migration: Cytoskeletal reorganization
- Angiogenesis: VEGF expression induction
EGFR is widely expressed in the brain[@ionescu2022][@chen2023]:
- Pyramidal neurons in cortex
- Hippocampal neurons (CA1-CA3)
- Dopaminergic neurons in substantia nigra
- Cerebellar Purkinje cells
- Astrocytes: High EGFR expression, particularly reactive astrocytes
- Oligodendrocyte precursor cells: Proliferation and differentiation
- Microglia: Low basal expression, upregulated in inflammation
- Alzheimer's Disease: Upregulated in cortex and hippocampus
- Parkinson's Disease: Altered in substantia nigra
- Aging: Reduced neuronal expression
- Brain injury: Induced in reactive astrocytes
During development, EGFR plays essential roles:
- Neural progenitor proliferation
- Neuronal differentiation
- Axon guidance
- Synapse formation
- Gliogenesis
In mature brain, EGFR contributes to:
- Synaptic plasticity: Modulates LTP and LTD
- Cognitive function: Spatial learning and memory
- Metabolic support: Astrocyte-neuron metabolic coupling
- Repair: Response to injury
EGF and EGFR provide critical trophic support:
- Promotes neuron survival
- Supports dendritic arborization
- Enhances synaptic connectivity
- Protects against excitotoxicity
EGFR has complex and multifaceted roles in Alzheimer's Disease[@zhang2017][@chaudhury2023][@wang2021]:
- Increased EGFR expression: In AD brain, particularly in affected regions
- Altered signaling: Constitutive activation in some contexts
- Astrocytic upregulation: Strong EGFR expression in reactive astrocytes
- Direct interaction: Aβ can bind EGFR and activate signaling
- Bidirectional relationship: EGFR activation increases amyloid precursor protein (APP) processing
- Synergistic toxicity: EGFR activation enhances Aβ-induced neuronal death
EGFR is implicated in tau pathology through multiple mechanisms[@patel2021]:
- Tau phosphorylation: EGFR signaling can increase tau kinases (GSK-3β, CDK5)
- Tau aggregation: Enhanced by EGFR-mediated cellular stress
- Tau spread: May facilitate propagation via astrocyte networks
- Excessive signaling: Chronic EGFR activation disrupts synaptic homeostasis
- Synaptic loss: Contributes to early cognitive decline
- Network dysfunction: Alters neural circuit stability
Targeting EGFR in AD presents both opportunities and challenges[@xu2024]:
Potential benefits:
- Reducing Aβ-induced toxicity
- Modulating neuroinflammation
- Protecting synaptic function
Concerns:
- Complexity of EGFR signaling
- Potential for receptor downregulation effects
In Parkinson's Disease, EGFR plays context-dependent roles[@luo2020]:
- Neuroprotection: EGF promotes dopaminergic neuron survival
- Mitochondrial function: EGFR signaling supports mitochondrial health
- Oxidative stress: Modulates oxidative stress responses
- Astrocytic EGFR: Upregulated in PD substantia nigra
- Neuroinflammation: Contributes to inflammatory environment
- Reactive gliosis: Promotes astrocyte reactivity
- Neuroprotective agents: EGF and EGFR agonists under investigation
- Combination approaches: With dopaminergic therapies
¶ Brain Injury and Stroke
- Upregulated in response to injury
- Promotes neural repair
- Angiogenesis induction
- Altered expression in epileptic tissue
- Contributes to aberrant neurogenesis
- Demyelination and remyelination roles
- Oligodendrocyte precursor cell regulation
- Genetic variants associated with ASD risk
- Synaptic development implications
¶ Neuroinflammation and Glial Function
EGFR plays significant roles in neuroinflammation[@hajjar2023]:
- Reactive astrogliosis: Strong EGFR upregulation in activated astrocytes
- Cytokine production: Modulates inflammatory mediator release
- Scar formation: Contributes to glial scar in injury
- Low basal expression in microglia
- Induction by inflammatory signals
- Modulates microglial phenotype
- EGFR signaling can both promote and suppress inflammation
- Context-dependent effects
- Important for understanding disease progression
¶ EGFR and Aging
With normal aging, EGFR exhibits[@chen2023]:
- Reduced neuronal expression
- Altered signaling efficiency
- Decreased trophic support
- Contributes to cognitive decline
These age-related changes may predispose to neurodegenerative processes.
Several strategies are being explored[@singh2022][@xu2024]:
-
EGFR inhibitors
- Tyrosine kinase inhibitors (TKIs) used in cancer
- May reduce pathological EGFR signaling
- Potential neuroprotective effects
-
EGFR agonists
- EGF and EGF mimetics
- May enhance trophic support
- Support neuronal survival
-
Allosteric modulators
- Targeted at extracellular domain
- More selective modulation
- Blood-brain barrier penetration
- Optimal dosing and timing
- Balancing protective vs. pathogenic signaling
- Side effect management
- Biomarker development for patient selection
- Combination therapy approaches
- Personalized treatment strategies
- Western blot analysis
- Immunohistochemistry
- qPCR and RNA sequencing
- Neuronal cell cultures
- Astrocyte cultures
- iPSC-derived neurons
- Transgenic mice
- AAV-mediated gene delivery
- Knockout/knockin models
- PET imaging with EGFR ligands
- Biomarker analysis
- Clinical trials of EGFR modulators
- Yarden & Sliwkowski, ErbB signaling (2001)
- Zhang et al., EGFR in Alzheimer's disease (2017)
- Kumar et al., EGF and EGFR in neural development (2020)
- Ionescu et al., EGFR in neurodegeneration (2022)
- Chaudhury et al., EGFR dysregulation in AD (2023)
- Patel et al., EGFR and tau pathology (2021)
- Luo et al., EGFR in PD (2020)
- Singh et al., EGFR inhibitors as neuroprotective (2022)
- Wang et al., EGFR and amyloid-beta interaction (2021)
- Hajjar et al., EGFR in neuroinflammation (2023)
- Xu et al., EGFR-targeted therapy for neurodegeneration (2024)
- Chen et al., EGFR and brain aging (2023)
- Yarden Y, Sliwkowski MX, ErbB signaling: biology and targeted therapy (2001)
- Zhang Y et al, EGFR in Alzheimer's disease: role and therapeutic potential (2017)
- Kumar A et al, EGF and EGFR in neural development and repair (2020)
- Ionescu A et al, EGFR signaling in neurodegeneration and regeneration (2022)
- Chaudhury S et al, EGFR dysregulation in Alzheimer's disease brain (2023)
- Patel K et al, EGFR and tau pathology in AD (2021)
- Luo L et al, EGFR in Parkinson's disease dopaminergic neurons (2020)
- Singh R et al, EGFR inhibitors as neuroprotective agents (2022)
- Wang J et al, EGFR and amyloid-beta interaction (2021)
- Hajjar SM et al, EGFR in neuroinflammation and glial activation (2023)
- Xu L et al, EGFR-targeted therapy for neurodegenerative diseases (2024)
- Chen W et al, EGFR and brain aging (2023)